Fast Track

You have full text access to this OnlineOpen article

EUROGIN 2008 roadmap on cervical cancer prevention†

  1. Silvia Franceschi1,
  2. Jack Cuzick2,
  3. Rolando Herrero3,
  4. Joakim Dillner4,
  5. Cosette M. Wheeler5,‡,*

Article first published online: 11 JUN 2009

DOI: 10.1002/ijc.24634

Issue

International Journal of Cancer

International Journal of Cancer

Volume 125, Issue 10, pages 2246–2255, 15 November 2009

Additional Information

How to Cite

Franceschi, S., Cuzick, J., Herrero, R., Dillner, J. and Wheeler, C. M. (2009), EUROGIN 2008 roadmap on cervical cancer prevention. Int. J. Cancer, 125: 2246–2255. doi: 10.1002/ijc.24634

Author Information

  1. 1

    International Agency for Research on Cancer, Lyon, France

  2. 2

    Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

  3. 3

    Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica

  4. 4

    Department of Medical Microbiology, Malmö University Hospital, Lund University, Malmö, Sweden

  5. 5

    House of Prevention Epidemiology (HOPE), University of New Mexico Health Sciences Center, Albuquerque, NM

  1. ‡

    Fax: +1-505-277-0265.

*House of Prevention Epidemiology (HOPE), University of New Mexico Health Sciences Center, 1816 Sigma Chi Rd NE, Albuquerque, NM 87106, USA

  1. †

    Conflicts of interest: Dr. C. Wheeler has received funding through her institution for equipment and reagents for HPV genotyping from Roche Molecular Systems and to conduct studies related to HPV vaccines from Merck and Co., Inc. and Glaxo SmithKline. Dr. J. Cuzick reports participation in Advisory Boards (GenProbe, GlaxoSmithKline, Roche); receipt of Research Grants (Qiagen, Roche, Gen Probe, Genomica, MTM) and participation in Speakers Bureau (Qiagen). Dr. R. Herrero is the co-principal investigator of the Costa Rica HPV vaccine trial, sponsored and funded by the United States National Cancer Institute (NCI) (contract N01-CP-11005), with funding support from the National Institutes of Health Office for Research on Women's Health, and conducted with support from the Ministry of Health of Costa Rica. Vaccine was provided for the Cosa Rica trial by GSK Biologicals, under a Clinical Trials Agreement with the NCI. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. The NCI and Costa Rica investigators are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data, and are not funded by vaccine manufacturing companies. Dr. J. Dillner reports participation in Advisory Board (Merck & Co., Inc.); has acted as a consultant (Merck & Co., Inc.); receipt of Research Grants (Merck & Co., Inc.) and participation in a Steering Committee (Merck & Co., Inc.). Dr. S. Franceschi has no conflict of interest to declare.

  2. ‡

    Fax: +1-505-277-0265.

Publication History

  1. Issue published online: 18 SEP 2009
  2. Article first published online: 11 JUN 2009
  3. Manuscript Accepted: 26 MAY 2009
  4. Manuscript Received: 23 MAY 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (229K)

References

  • 1
    Schiller JT,Castellsagué X,Villa LL,Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26( Suppl 10): K53–K61.
  • 2
    Hildesheim A,Herrero R,Wacholder S,Rodriguez AC,Solomon D,Bratti MC,Schiller JT,Gonzalez P,Dubin G,Porras C,Jimenez SE,Lowy DR. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743–53.
  • 3
    The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–8.
  • 4
    WHO Strategic Advisory Group of Experts (SAGE). Meeting of the immunization Strategic Advisory Group of Experts, November 2008—conclusions and recommendations. Wkly Epidemiol Rec 2009; 84: 1–16.
  • 5
    Kim JJ,Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl. J Med 2008; 359: 821–32.
  • 6
    Barr E,Sings HL. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine 2008; 26: 6244–57.
  • 7
    Brotherton JML,Deeks SL,Campbell-Lloyd S,Misrachi A,Passaris I,Peterson K,Pitcher H,Scully M,Watson M,Webby R. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun. Dis. Intell 2008; 32: 457–61.
  • 8
    King LA,Levy-Bruhl D,O'Flanagan D,Bacci S,Lopalco PL,Kudjawu Y,Salmaso S. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill 2008; 13(33):p ii: 18954.
  • 9
    Koulova A,Tsui J,Irwin K,Van DP,Biellik R,Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008; 26: 6529–41.
  • 10
    Goldie SJ,Diaz M,Kim SY,Levin CE,Van MH,Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26( Suppl 12): M17–M29.
  • 11
    Wheeler CM,Franceschi S. EUROGIN 2007 roadmap—conclusion. Vaccine 2008; 26( Suppl 1): A28–A31.
  • 12
    Wright TC,Jr,Bosch FX. Is viral status needed before vaccination?. Vaccine 2008; 26( Suppl 1): A12–A15.
  • 13
    Sycuro LK,Xi LF,Hughes JP,Feng Q,Winer RL,Lee SK,O'Reilly S,Kiviat NB,Koutsky LA. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198: 971–8.
  • 14
    Harper DM,Paavonen J. Age for HPV vaccination. Vaccine 2008; 26( Suppl 1): A7–11.
  • 15
    Muñoz N, Manalastas R, Jr, Pitisuttihum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity and efficacy of quadrivalent human papillomavirus types (6,11,16,18) recombinant vaccine in women aged 24–45 years: a randomised double-blind trial. Lancet 2009; 373: 1949–57.
  • 16
    Paavonen J,Jenkins D,Bosch FX,Naud P,Salmeron J,Wheeler CM,Chow SN,Apter DL,Kitchener HC,Castellsague X,de Carvalho NS,Skinner S, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–70.
  • 17
    Brown DR,Kjaer SK,Sigurdsson K,Iversen OE,Hernandez-Avila M,Wheeler CM,Perez G,Koutsky LA,Tay EH,Garcia P,Ault KA,Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199: 926–35.
  • 18
    Wheeler CM,Kjaer SK,Sigurdsson K,Iversen OE,Hernandez-Avila M,Perez G,Brown DR,Koutsky LA,Tay EH,Garcia P,Ault KA,Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199: 936–44.
  • 19
    Franco EL,Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26( Suppl 1): A16–A23.
  • 20
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095–101.
  • 21
    Mayrand MH,Duarte-Franco E,Rodrigues I,Walter SD,Hanley J,Ferenczy A,Ratnam S,Coutlee F,Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579–88.
  • 22
    Ronco G,Segnan N,Giorgi-Rossi P,Zappa M,Casadei GP,Carozzi F,Dalla Palma P,Del Mistro A,Folicaldi S,Gillio-Tos A,Nardo G,Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765–74.
  • 23
    Cuzick J,Szarewski A,Mesher D,Cadman L,Austin J,Perryman K,Ho L,Terry G,Sasieni P,Dina R,Soutter WP. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—results from the Hammersmith study. Int J Cancer 2008; 122: 2294–300.
  • 24
    Bulkmans N,Berkhof J,Rozendaal L,van Kemenade FJ,Boeke A,Bulk S,Voorhorst FJ,Verheijen RH,van Groningen K,Boon ME,Ruitinga W,van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764–72.
  • 25
    Naucler P,Ryd W,Tornberg S,Strand A,Wadell G,Elfgren K,Radberg T,Strander B,Johnasson B,Forslund O,Hansson BG,Rylander E, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97.
  • 26
    Dillner J,Rebolj M,Birembaut P,Petry KU,Szarewski A,Munk C,de Sanjos S,Naucler P,Lloveras B,Kjaer S,Cuzick J,Van Ballegooijen M, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
  • 27
    Sadler L,Saftlas A,Wang W,Exeter M,Whittaker J,McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004; 291: 2100–6.
  • 28
    Arbyn M,Kyrgiou M,Simoens C,Raifu AO,Koliopoulos G,Martin-Hirsch P,Prendiville W,Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284.
  • 29
    Ronco G,Giorgi-Rossi P,Carozzi F,Confortini M,Dalla Palma P,Del Mistro A,Gillio-Tos A,Minucci D,Naldoni C,Rizzolo R,Schincaglia P,Volante R, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492–501.
  • 30
    Franceschi S,Clifford GM. Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 938–9.
  • 31
    Smith JS,Lindsay L,Hoots B,Keys J,Franceschi S,Winer R,Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621–32.
  • 32
    Carozzi F,Confortini M,Dalla Palma P,Del Mistro A,Gillio-Tos A,De Marco L,Giorgi-Rossi P,Pontenani G,Rosso S,Sani C,Sintoni C,Segnan N, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937–45.
  • 33
    Sankaranarayanan R,Nene BM,Shastri SS,Jayant K,Muwonge R,Budukh AM,Hingmire S,Malvi SG,Thorat R,Kothari A,Chinoy R,Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385–94.
  • 34
    Qiao YL,Sellors JW,Eder PS,Bao YP,Lim JM,Zhao FH,Weigl B,Zhang WH,Peck RB,Li L,Chen F,Pan QJ, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929–36.
  • 35
    Muñoz N,Franco EL,Herrero R,Andrus JK,de Quadros C,Goldie SJ,Bosch FX. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26( Suppl 11): L96–L107.
  • 36
    Franco EL,Tsu V,Herrero R,Lazcano-Ponce E,Hildesheim A,Muñoz N,Murillo R,Sanchez GI,Andrua JK. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008; 26( Suppl 11): L88–L95.
  • 37
    Cuzick J,Arbyn M,Sankaranarayanan R,Tsu V,Ronco G,Mayrand MH,Dillner J,Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26( Suppl 10): K29–K41.
  • 38
    Depuydt CE,Arbyn M,Benoy IH,Vandepitte J,Vereecken AJ,Bogers JJ. Quality control for normal liquid based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection? J Cell Mol Med, in press.
  • 39
    Muñoz N,Bosch FX,de Sanjosé S,Herrero R,Castellsagué X,Shah KV,Snijders PJ,Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27.
  • 40
    Villa LL,Costa RL,Petta CA,Andrade RP,Ault KA,Giuliano AR,Wheeler CM,Koutsky LA,Malm C,Lehtinen M,Skjeldestad FE,Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–8.
  • 41
    Villa LL,Ault KA,Giuliano AR,Costa RL,Petta CA,Andrade RP,Brown DR,Ferenczy A,Harper DM,Koutsky LA,Kurman RJ,Lehtinen M, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571–83.
  • 42
    Nardelli-Haefliger D,Lurati F,Wirthner D,Spertini F,Schiller JT,Lowy DR,Ponci F,De Grandi P. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005; 23: 3634–41.
  • 43
    Manuri PR,Nehete B,Nehete PN,Reisenauer R,Wardell S,Courtney AN,Gambhira R,Lomada D,Chopra AK,Sastry KJ. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25: 3302–10.
  • 44
    Streatfield SJ,Howard JA. Plant-based vaccines. Int J Parasitol 2003; 33: 479–93.
  • 45
    Paz De la Rosa GP,Monroy-Garcia A,Mora-Garcia MD,Pena CG,Hernandez-Montes J,Weiss-Steider B,Gomez Lim MA. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009; 6: 2.
  • 46
    Fernandez-San MA,Ortigosa SM,Hervas-Stubbs S,Corral-Martinez P,Segui-Simarro JM,Gaetan J,Coursaget P,Veramendi J. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008; 6: 427–41.
  • 47
    Warzecha H,Mason HS,Lane C,Tryggvesson A,Rybicki E,Williamson AL,Clements JD,Rose RC. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003; 77: 8702–11.
  • 48
    Maclean J,Koekemoer M,Olivier AJ,Stewart D,Hitzeroth II,Rademacher T,Fischer R,Williamson AL,Rybicki EP. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007; 88(Part 5): 1460–9.
  • 49
    Ohlschlager P,Osen W,Dell K,Faath S,Garcea RL,Jochmus I,Muller M,Pawlita M,Schafer K,Sehr P,Staib C,Sutter G. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003; 77: 4635–45.
  • 50
    Alphs HH,Gambhira R,Karanam B,Roberts JN,Jagu S,Schiller JT,Zeng W,Jackson DC,Roden RB. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008; 105: 5850–5.
  • 51
    Jagu S, Karanam B, Gambhira R, Chivukula SV, Chiganti RJ, Lowry DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101: 782–92.
  • 52
    Gambhira R,Jagu S,Karanam B,Gravitt PE,Culp TD,Christensen ND,Roden RB. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81: 11585–92.
  • 53
    Buck CB,Cheng N,Thompson CD,Lowy DR,Steven AC,Schiller JT,Trus BL. Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82: 5190–7.
  • 54
    Day PM,Gambhira R,Roden RB,Lowy DR,Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008; 82: 4638–46.
  • 55
    Selinka HC,Giroglou T,Nowak T,Christensen ND,Sapp M. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 2003; 77: 12961–7.
  • 56
    Richards RM,Lowy DR,Schiller JT,Day PM. Cleavage of the papillomavirus minor capsid protein. L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 2006; 103: 1522–7.
  • 57
    Kondo K,Ochi H,Matsumoto T,Yoshikawa H,Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 2008; 80: 841–6.
  • 58
    Kanda T,Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccin 2008; 5: 43–5.
  • 59
    Jabbar IA,Fernando GJ,Saunders N,Aldovini A,Young R,Malcolm K,Frazer IH. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000; 18: 2444–53.
  • 60
    Aires KA,Cianciarullo AM,Carneiro SM,Villa LL,Boccardo E,Perez-Martinez G,Perez-Arellano I,Oliveria ML,Ho PL. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 2006; 72: 745–52.
  • 61
    Yang XF,Qu XZ,Wang K,Zheng J,Si LS,Dong XP,Wang YL. Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42. Acta Biochim Biophys Sin (Shanghai). 2005; 37: 743–50.
  • 62
    Baud D,Ponci F,Bobst M,De GP,Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004; 78: 12901–9.
  • 63
    Cantarella G,Liniger M,Zuniga A,Schiller JT,Billeter M,Naim HY,Glueck R. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009; 27: 3385–90.
  • 64
    Griffin DE. Measles virus. In: KnipeDM,HowleyPM, editors. Fields virology, 5th edn., vol. 2. Philadelphia: Lippincott, Williams, Wilkins, 2007. 1551–85.
  • 65
    Jochmus I,Schafer K,Faath S,Muller M,Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999; 30: 269–74.
  • 66
    Schreckenberger C,Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004; 16: 485–91.
  • 67
    Karanam B,Gambhira R,Peng S,Jagu S,Kim DJ,Ketner GW,Stern PL,Adams RJ,Roden RB. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009; 27: 1040–9.
  • 68
    Bian T,Wang Y,Lu Z,Ye Z,Zhao L,Ren J,Zhang H,Ruan L,Tian H. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther 2008; 7: 1329–35.
  • 69
    Qian J,Dong Y,Pang YY,Ibrahim R,Berzofsky JA,Schiller JT,Khleif SN. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006; 118: 3022–9.
  • 70
    Wheeler CM,Hunt WC,Joste NE,Key CR,Quint WG,Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475–87.
  • 71
    Carreon JD,Sherman ME,Guillen D,Solomon D,Herrero R,Jeronimo J,Wacholder S,Rodriguez AC,Morales J,Hutchinson M,Burk RD,Schiffman M. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441–6.
  • 72
    Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110(3 Suppl 1 ): S18–S25.
  • 73
    Pedersen C,Petaja T,Strauss G,Rumke HC,Poder A,Richardus JH,Spiessens B,Descamps D,Hardt K,Lehtinen M,Dubin G. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40: 564–71.
  • 74
    Giuliano AR. Burden of HPV in males: design of an efficacy trial of a prophylactic HPV 6/11/16/18 vaccine among men aged 16–26 years. EUROGIN 2008, Nice, France, 12–15 November 2008, Abstract SS 19–7.
  • 75
    Joura EA,Leodolter S,Hernandez-Avila M,Wheeler CM,Perez G,Koutsky LA,Garland SM,Harper DM,Tang GW,Ferris DG,Steben M,Jones RW, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–702.
  • 76
    Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475–87.
  • 77
    Dillner J,Arbyn M,Dillner L. Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007; 148: 199–207.
  • 78
    Dillner L,Dillner J. International quality assurance of human papillomavirus testing. Cent Eur J Public Health 16: S16–S20, 2008.
  • 79
    Ferguson M,Wilkinson DE,Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24–25 January 2008, Geneva, Switzerland. Vaccine 2009; 27: 337–47.
  • 80
    Sasieni P,Adams J,Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 88–93.
View Full Article (HTML) Get PDF (229K)